DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Glyburide and Metformin (Glyburide / Metformin Hydrochloride) - Published Studies

 
 



Published Studies Related to Glyburide and Metformin (Glyburide / Metformin)

Well-designed clinical trials related to Glyburide and Metformin (Glyburide / Metformin)

Saxagliptin, a potent, selective inhibitor of DPP-4, does not alter the pharmacokinetics of three oral antidiabetic drugs (metformin, glyburide or pioglitazone) in healthy subjects. [2011.07]

Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. [2011.05]

Effects of rosiglitazone, glyburide, and metformin on beta-cell function and insulin sensitivity in ADOPT. [2011.05]

Comparison of pioglitazone vs glyburide in early heart failure: insights from a randomized controlled study of patients with type 2 diabetes and mild cardiac disease. [2010.05]

Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. [2010.01]

Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes. [2010.01]

Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT). [2010.01]

Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes. [2010]

Comparison of extended-release metformin in combination with a sulfonylurea (glyburide) to sulfonylurea monotherapy in adult patients with type 2 diabetes: a multicenter, double-blind, randomized, controlled, phase III study. [2007.05]

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [2006.12.07]

Investigation of the pharmacokinetic and pharmacodynamic interactions between memantine and glyburide/metformin in healthy young subjects: a single-center, multiple-dose, open-label study. [2005.10]

PRESERVE-beta: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. [2005.09]

Well-designed clinical trials possibly related to Glyburide and Metformin (Glyburide / Metformin)

Effects of Juglans regia L. leaf extract on hyperglycemia and lipid profiles in type two diabetic patients: a randomized double-blind, placebo-controlled clinical trial. [2014]

Anti-hyperglycemic and anti-hypercholesterolemic effects of Aloe vera leaf gel in hyperlipidemic type 2 diabetic patients: a randomized double-blind placebo-controlled clinical trial. [2012]

Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes. [2011.07]

Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load. [2011.06]

Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes. [2011]

A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. [2010.05]

Exenatide versus glibenclamide in patients with diabetes. [2010.03]

Psychometric evaluation of the Diabetes Symptom Checklist-Revised (DSC-R)--a measure of symptom distress. [2009.11]

Efficacy of glimepiride/metformin combination versus glibenclamide/metformin in patients with uncontrolled type 2 diabetes mellitus. [2009.11]

Effect of two starting insulin regimens in patients with type II diabetes not controlled on a combination of oral antihyperglycemic medications. [2009.05]

Comparison of glycaemic control in patients with Type 2 diabetes on basal insulin and fixed combination oral antidiabetic treatment: results of a pilot study. [2009.03]

Nateglinide and glibenclamide metabolic effects in naive type 2 diabetic patients treated with metformin. [2009.02]

Benefits and risks of oral diabetes agents compared with insulin in women with gestational diabetes: a systematic review. [2009.01]

A randomized, controlled trial of the effects of rosiglitazone on adipokines, and inflammatory and fibrinolytic markers in diabetic patients: study design and protocol. [2008.10]

The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia. [2008.06]

Effects of pioglitazone in combination with metformin or a sulfonylurea compared to a fixed-dose combination of metformin and glibenclamide in patients with type 2 diabetes. [2007.08]

Simultaneous assay of metformin and glibenclamide in human plasma based on extraction-less sample preparation procedure and LC/(APCI)MS. [2007.07.01]

Oral antidiabetic agents in pregnancy and lactation: a paradigm shift? [2007.07]

Oral Antidiabetic Agents in Pregnancy and Lactation: A Paradigm Shift? (July/August). [2007.05.29]

[ADOPT study: which first-line glucose-lowering oral medication in type 2 diabetes?] [2007.01]

Effects of nateglinide and glibenclamide on prothrombotic factors in naive type 2 diabetic patients treated with metformin: a 1-year, double-blind, randomized clinical trial. [2007]

A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe. [2006.12]

Insulins and oral hypoglycemic agents in pregnancy. [2006.11]

Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. [2006.10]

The Pro12Ala variant of the PPARG gene is a risk factor for peroxisome proliferator-activated receptor-gamma/alpha agonist-induced edema in type 2 diabetic patients. [2006.09]

Glycaemic and nonglycaemic effects of pioglitazone in triple oral therapy of patients with type 2 diabetes. [2006.08]

An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with glibenclamide as adjunctive therapy in patients with type 2 diabetes poorly controlled on metformin. [2006.08]

Beta-cell response to metformin-glibenclamide combination tablets (Glucovance) in patients with type 2 diabetes. [2006.07]

Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy. [2006.03]

Improving metabolic control leads to better working memory in adults with type 2 diabetes. [2006.02]

Biphasic insulin aspart 30 plus metformin: an effective combination in type 2 diabetes. [2006.01]

Other research related to Glyburide and Metformin (Glyburide / Metformin)

Impaired renal function modifies the risk of severe hypoglycaemia among users of insulin but not glyburide: a population-based nested case-control study. [2011.06]

Metformin compared with glyburide for the management of gestational diabetes. [2010.10]

Determination of metformin hydrochloride and glyburide in an antihyperglycemic binary mixture using high-performance liquid chromatographic-UV and spectrometric methods. [2010.01]

Comparison of pioglitazone vs glyburide in early heart failure: insights from a randomized controlled study of patients with type 2 diabetes and mild cardiac disease. [2010]

Metformin compared with glyburide for the management of gestational diabetes. [2010]

Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. [2010]

Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT). [2010]

Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. [2009.04]

Effect of chronic rosiglitazone, metformin and glyburide treatment on beta-cell mass, function and insulin sensitivity in mZDF rats. [2008.09]

Cardiovascular, metabolic and hormonal responses to the progressive exercise performed to exhaustion in patients with type 2 diabetes treated with metformin or glyburide. [2008.03]

Effect of glyburide-metformin combination tablet in patients with type 2 diabetes. [2007.11]

Other possibly related research studies

[Probability of control of the patient with diabetes exclusively treated with pharmacological therapy] [2006.07]

Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study. [2006.06]

Diet and medical therapy in the optimal management of gestational diabetes mellitus. [2006]

Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin. [2006.11]

Insulin secretion and sensitivity as determinants of HbA1c in type 2 diabetes. [2006.04]

Apparent resolution of type 2 diabetes mellitus after initiation of potent antiretroviral therapy in a man from Africa with HIV infection. [2006.05.15]

Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. [2006.01.17]

Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. [2005]

Willingness to pay for inhaled insulin: a contingent valuation approach. [2005]

Mitochondrial dysfunction as the cause of the failure to precondition the diabetic human myocardium. [2006.02.01]

Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. [2005.11.23]

Pemphigus vulgaris triggered by glibenclamide and cilazapril. [2005]

Cardiovascular risk factors associated with insulin resistance: effects of oral antidiabetic agents. [2005]

[Use of oral lipid-lowering drugs in patients with type-2 diabetes mellitus] [2005.04.30]

Evaluation of drug therapy and risk factors in diabetic hypertensives: a study of the quality of care provided in diabetic clinics in Bahrain. [2005.04]

Diabetes mellitus in a domesticated Spanish mustang. [2005.02.15]

Exenatide: A Review of Its Use in Patients with Type 2 Diabetes Mellitus (as an Adjunct to Metformin and/or a Sulfonylurea). [2007]

Improvement in coronary vascular dysfunction produced with euglycaemic control in patients with type 2 diabetes. [2007.03]

The new clinical trials with thiazolidinediones - DREAM, ADOPT, and CHICAGO: promises fulfilled? [2007.08]

A comparative study of the effects of hypoglycemic agents on serum electrolytes in the diabetic patients. [2007.01]

Regulation of the atherogenic properties of vascular smooth muscle proteoglycans by oral anti-hyperglycemic agents. [2007.03]

Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus. [2007.11]

Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment-naive elderly patients with type 2 diabetes. [2007.10.17]

Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality. [2007.09]

Pharmacological management of gestational diabetes: an overview. [2007.07]

Impact of Fixed-Dose Combination Drugs on Adherence to Prescription Medications. [2008.02.21]

Rosiglitazone Associated Fractures in Type 2 Diabetes: An Analysis From ADOPT. [2008.02.05]

Effects of Persea americana Mill (Lauraceae) ["Avocado"] ethanolic leaf extract on blood glucose and kidney function in streptozotocin-induced diabetic rats and on kidney cell lines of the proximal (LLCPK1) and distal tubules (MDBK). [2008.01]

Sitagliptin: a novel agent for the management of type 2 diabetes mellitus. [2008.03.15]

Impact of fixed-dose combination drugs on adherence to prescription medications. [2008.05]

Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). [2008.05]

Increased hematocrit and reduced blood pressure following control of glycemia in diabetes. [2008]

New use of rosiglitazone decreased following publication of a meta-analysis suggesting harm. [2008.07]

Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France. [2008.06]

Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment-naive elderly patients with type 2 diabetes. [2008.08]

Risk of coronary artery disease associated with initial sulphonylurea treatment of patients with type 2 diabetes: a matched case-control study. [2008.12]

[Poisonings by oral antidiabetic drugs in Spain. Analysis and evolution during 13 years (1991-2003)] [2008.06]

Alogliptin Use in Elderly People: A Pooled Analysis from Phase 2 and 3 Studies. [2009.09.30]

Selecting among ADA/EASD tier 1 and tier 2 treatment options. [2009.09]

Diagnosis and management of gestational diabetes mellitus. [2009.07.01]

Insulin-based versus triple oral therapy for newly diagnosed type 2 diabetes: which is better? [2009.10]

The management of gestational diabetes. [2009]

Balancing risk and benefit with oral hypoglycemic drugs. [2009.06]

Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications. [2009.02]

Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. [2010.09]

Role of saxagliptin as monotherapy or adjunct therapy in the treatment of type 2 diabetes. [2010.05.25]

Type 2 diabetes mellitus with pancreatic beta cell dysfunction in 3 horses confirmed with minimal model analysis. [2009.12]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017